LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity.

LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity.

LY2857785 is a potent and selective CDK9 inhibitor; significantly reduces RNAP II CTD phosphorylation and dramatically decreases MCL1 protein levels to result in apoptosis in a variety of leukemia and solid tumor cell lines.

LY2857785 is a potent and selective CDK9 inhibitor; significantly reduces RNAP II CTD phosphorylation and dramatically decreases MCL1 protein levels to result in apoptosis in a variety of leukemia and solid tumor cell lines.

LY2857785 is a potent and selective CDK9 inhibitor; significantly reduces RNAP II CTD phosphorylation and dramatically decreases MCL1 protein levels to result in apoptosis in a variety of leukemia and solid tumor cell lines.

LY2886721 is a novel potent agent that is used to treat Alzheimer’s Disease in preclinical experiments.

LY2886721 is a novel potent agent that is used to treat Alzheimer’s Disease in preclinical experiments.

LY2886721 is a novel potent agent that is used to treat Alzheimer’s Disease in preclinical experiments.

LY2886721 is a novel potent agent that is used to treat Alzheimer’s Disease in preclinical experiments.

LY294002 is a PI3k inhibitor (cell IC50 about 10 ??M) and a casein kinase II inhibitor.

LY294002 is a PI3k inhibitor (cell IC50 about 10 ??M) and a casein kinase II inhibitor.

LY294002 is a PI3k inhibitor (cell IC50 about 10 ??M) and a casein kinase II inhibitor.

LY294002 is a PI3k inhibitor (cell IC50 about 10 ??M) and a casein kinase II inhibitor.

LY2940680 has been shown to affect a cancer cell signaling pathway initiated by the Hedgehog (Hh) protein.

LY2940680 has been shown to affect a cancer cell signaling pathway initiated by the Hedgehog (Hh) protein.

LY2940680 has been shown to affect a cancer cell signaling pathway initiated by the Hedgehog (Hh) protein.

LY2940680 has been shown to affect a cancer cell signaling pathway initiated by the Hedgehog (Hh) protein.

LY3039478 is a orally bioavailable, novel small molecule Notch inhibitor with an IC50 of ~1nM in most of the tumor cell lines tested.

LY3039478 is a orally bioavailable, novel small molecule Notch inhibitor with an IC50 of ~1nM in most of the tumor cell lines tested.

LY3039478 is a orally bioavailable, novel small molecule Notch inhibitor with an IC50 of ~1nM in most of the tumor cell lines tested.

LY310762 is a 5-HT1D-preferring receptor antagonist (EC50 = 31 nM).

LY310762 is a 5-HT1D-preferring receptor antagonist (EC50 = 31 nM).

LY310762 is a 5-HT1D-preferring receptor antagonist (EC50 = 31 nM).

LY310762 is a 5-HT1D-preferring receptor antagonist (EC50 = 31 nM).

LY315920 (Varespladib) is an inhibitor of the IIa, V, and X isoforms of secretory phospholipase A2 (sPLA2).

LY315920 (Varespladib) is an inhibitor of the IIa, V, and X isoforms of secretory phospholipase A2 (sPLA2).

LY315920 (Varespladib) is an inhibitor of the IIa, V, and X isoforms of secretory phospholipase A2 (sPLA2).

LY315920 (Varespladib) is an inhibitor of the IIa, V, and X isoforms of secretory phospholipase A2 (sPLA2).

LY317615 (Enzastaurin) is a potent and selective inhibitor of PKC?? with antiproliferative activity (IC50= ~6 nM).

LY317615 (Enzastaurin) is a potent and selective inhibitor of PKC?? with antiproliferative activity (IC50= ~6 nM).

LY317615 (Enzastaurin) is a potent and selective inhibitor of PKC?? with antiproliferative activity (IC50= ~6 nM).

LY317615 (Enzastaurin) is a potent and selective inhibitor of PKC?? with antiproliferative activity (IC50= ~6 nM).

LY335979 (Zosuquidar trihydrochloride) is a potent highly selective P-gp inhibitor.

LY335979 (Zosuquidar trihydrochloride) is a potent highly selective P-gp inhibitor.

LY335979 (Zosuquidar trihydrochloride) is a potent highly selective P-gp inhibitor.

LY335979 (Zosuquidar trihydrochloride) is a potent highly selective P-gp inhibitor.

LY 341495 has been shown to be a highly potent and selective group II metabotropic glutamate receptor (mGluR-2) antagonist with Ki / IC50 values are 2.3, 1.3, 173, 990, 6800, 8200 and 22000 nM for human mGluR-2, mGluR-3, mGluR-8 , mGluR-7a, mGluR-1a, mGluR-5a and mGluR-4a.

LY 341495 has been shown to be a highly potent and selective group II metabotropic glutamate receptor (mGluR-2) antagonist with Ki / IC50 values are 2.3, 1.3, 173, 990, 6800, 8200 and 22000 nM for human mGluR-2, mGluR-3, mGluR-8 , mGluR-7a, mGluR-1a, mGluR-5a and mGluR-4a.

LY 341495 has been shown to be a highly potent and selective group II metabotropic glutamate receptor (mGluR-2) antagonist with Ki / IC50 values are 2.3, 1.3, 173, 990, 6800, 8200 and 22000 nM for human mGluR-2, mGluR-3, mGluR-8 , mGluR-7a, mGluR-1a, mGluR-5a and mGluR-4a.

LY364947 is a diheteroaryl-substituted pyrazole compound used as a selective, ATP-competitive inhibitor of TGF-??RI (TGF-?? Receptor I kinase).

LY364947 is a diheteroaryl-substituted pyrazole compound used as a selective, ATP-competitive inhibitor of TGF-??RI (TGF-?? Receptor I kinase).

LY364947 is a diheteroaryl-substituted pyrazole compound used as a selective, ATP-competitive inhibitor of TGF-??RI (TGF-?? Receptor I kinase).

LY404187 is a selective, potent and centrally active positive allosteric modulator of AMPA receptors.

LY404187 is a selective, potent and centrally active positive allosteric modulator of AMPA receptors.

LY404187 is a selective, potent and centrally active positive allosteric modulator of AMPA receptors.